Back to News
Market Impact: 0.2
Leerink Partners Initiates Coverage of Amneal Pharmaceuticals at Outperform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Leerink Partners initiated coverage of Amneal Pharmaceuticals (NASDAQGS: AMRX) with an Outperform rating on September 9, 2026. AMRX closed at $17.27 that day, up from a pre-action close of $17.05, a gain of roughly 1.3%.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
AMRX0.45
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Goldman says these top tech stocks have plenty of upside ahead of earnings
- ProPetro’s 49% decline: how Fair Value spotted the warning signs
- Persistent Oil Prices Threaten Inflation Outlook
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Could France’s debt crisis spread across Europe?